Evidence map›Paper›PMID 35772911›Full record

Trial reportJournal of the American College of Cardiology2022

Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.

Michael Böhm, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, Amr Abdin, Felix Mahfoud, Martina Brueckmann, Nicholas D Gollop, Tomoko Iwata and 6 more

Open access · hybridAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Cardiomyopathy in Older Adults.Current cardiology reports · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 7 countries.

Michael BöhmKlinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany. Electronic address: michael.boehm@uks.eu.
Javed ButlerDepartment of Medicine, University of Mississippi School of Medicine, Jackson, Mississippi, USA.
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
João Pedro FerreiraUniversité de Lorraine, Centre d'Investigation Clinique-Plurithématique Inserm 1433, Centre Hospitalier Regional Universitaire, Nancy Brabois, France; Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Stuart J PocockDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Amr AbdinKlinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany.
Felix MahfoudKlinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany.
Martina BrueckmannBoehringer Ingelheim International, Ingelheim, Germany; First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
Nicholas D GollopBoehringer Ingelheim International, Ingelheim, Germany.
Tomoko IwataBoehringer Ingelheim Pharma GmbH and Co KG, Biberach/Riss, Germany.
Piotr PonikowskiWroclaw Medical University, Wrocław, Poland.
Christoph WannerMedizinische Klinik und Poliklinik 1, Schwerpunkt Nephrologie, Universitätsklinikum Würzburg, Würzburg, Germany.
Faiez ZannadUniversité de Lorraine, Centre d'Investigation Clinique-Plurithématique Inserm 1433, Centre Hospitalier Regional Universitaire, Nancy Brabois, France; Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Milton PackerBaylor University Medical Center, Dallas, Texas, USA; Imperial College, London, United Kingdom.
Stefan D AnkerDepartment of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
EMPEROR-Preserved Trial Committees and Investigators
Boehringer Ingelheim (Germany) · DEUniversitätsklinikum des Saarlandes · DEInserm · FRBaylor University Medical Center · USBerlin-Brandenburger Centrum für Regenerative Therapien · DENational and Kapodistrian University of Athens · GRUniversitätsklinikum Würzburg · DEUniversity of London · GBUniversity of Mississippi Medical Center · USUniversity of Wrocław · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmpagliflozin reduces cardiovascular death (CVD) or heart failure (HF) hospitalization (HFH) in patients with HF and preserved ejection fraction. Treatment effects and safety in relation to age have not been studied.

objectivesThe purpose of this study was to evaluate the interplay of age and empagliflozin effects in EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction).

methodsWe grouped patients (n = 5,988) according to their baseline age (<65 years [n = 1,199], 65-74 years [n = 2,214], 75-79 years [n = 1,276], ≥80 years [n = 1,299]). We explored the influence of age on empagliflozin effects on CVD or HFH (primary outcome), total HFH, rate of decline in estimated glomerular filtration rate, health-related quality of life with the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score, and frequency of adverse events.

resultsConsidering only patients on placebo, the incidence of primary outcomes (P trend = 0.02) and CVD (P trend = 0.003) increased with age. Empagliflozin reduced primary outcomes (P trend = 0.33), first HFH (P trend = 0.22), and first and recurrent HFH (P trend = 0.11) across all age groups with an effect being similar at ≥75 years (P interaction = 0.22) or >80 years (P interaction = 0.51). Empagliflozin improved Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at week 52 and attenuated the decline of estimated glomerular filtration rate without age interaction (P = 0.48 and P = 0.32, respectively). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the age groups.

conclusionsEmpagliflozin reduced primary outcomes and first and recurrent HFH and improved symptoms across a broad age spectrum. High age was not associated with reduced efficacy or meaningful intolerability. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction [EMPEROR-Preserved]; NCT0305951).

Indexed as

Benzhydryl CompoundsGlucosidesHeart FailureAgedAged, 80 and overChronic DiseaseHumansMiddle AgedStroke VolumeTreatment OutcomeBenzhydryl CompoundsempagliflozinGlucosidesagecardiovascular outcomesempagliflozinheart failurekidney function

Identifiers

PMID35772911
OpenAlexW4283769275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.